Huahui Health
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HBV/HDV large envelope protein (PreS1 domain)Monoclonal antibody | Chronic Hepatitis BHepatitis Delta Chronic Hepatitis Delta | |
| Phase 1 | PD-1 / CTLA-4 / VEGF-AMultispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
September 2028 (1)
Est. primary completion 2028-09-12 · NCT07499544 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.